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Over the years chemotherapy failure has been a vital research topic as researchers
have been striving to discover reasons behind it. The extensive studies carried out on
chemotherapeutic agents confirm that resistance to chemotherapy is a major reason
for treatment failure. “Resistance to chemotherapy,” however, is a comprehensive
phrase that refers to a variety of different mechanisms in which ATP-binding cassette
(ABC) mediated efflux dominates. The ABC is one of the largest gene superfamily of
transporters among both eukaryotes and prokaryotes; it represents a variety of genes
that code for proteins, which perform countless functions, including drug efflux – a
natural process that protects cells from foreign chemicals. Up to date, chemotherapy
failure due to ABC drug efflux is an active research topic that continuously provides
further evidence on multiple drug resistance (MDR), aiding scientists in tackling and
overcoming this issue. This review focuses on drug resistance by ABC efflux transporters
in human, viral, parasitic, fungal and bacterial cells and highlights the importance of the
MDR permeability glycoprotein being the mutual ABC transporter among all studied
organisms. Current developments and future directions to overcome this problem are
also discussed.
Keywords: ABC family, multiple drug resistance, chemotherapy failure, chemotherapy efflux, p-glycoprotein,
BCRP1
INTRODUCTION
Millions of new cases with infectious/malignant diseases are reported every year; many of them
may die due to failure of therapy that is mainly attributed to resistance to chemotherapy (Teillant
et al., 2015; Crunkhorn, 2016; Saunders and Lon, 2016). Chemotherapy is a broad term that will
be utilized in this review to describe chemical agents or drugs used for treatment of different types
Abbreviations: ABC, ATP binding cassette; AML, acute myelogenous leukemia; BCRP, breast cancer resistance protein;
C. albicans, C. albicans; CCB, calcium channel blocker; CFTR, cystic fibrosis trans-membrane conductance regulator; COX-2,
cyclooxygenase-2; CSA, cyclosporine A; E. coli, Escherichia coli; E. faecalis, Enterococcus faecalis; MATE, multidrug and toxic
compound extrusion; MDR, multiple drug resistance; MFS, major facilitator superfamily; miRNA, micro RNA; MRP, multiple
resistance protein; MTX, methotrexate; NBD, nucleotide binding domain; pfMDR, plasmodium falciparum multiple drug
resistance; P-gp, P-glycoprotein; RND, resistance-nodulation-division; siRNA, small interference RNA; SMR, small multidrug
resistance; SNP, single nucleotide polymorphism; TMD, Trans-membrane domain.
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of diseases caused by many causative microorganisms including
virus, bacteria, fungi, parasites, or malignant diseases (Leekha
et al., 2011; Wijdeven et al., 2016).
Despite the success achieved in the management of many
conditions, we still have a never-ending constant battle against
the constantly evolving microorganisms and malignant cells that
strive for their own survival (Holohan et al., 2013; Blair et al.,
2015; Sanglard, 2016). This is mainly due to resistance, which
is a natural phenomenon and defense mechanism created and
developed to protect living cells, eukaryotic and prokaryotic, and
to maximize their survival.
There are a variety of mechanisms that living cells may
naturally have (intrinsic) or can develop from their environment
or genetic changes (acquired) that give them the adaptation to
resist foreign chemicals including chemotherapy (Swanton, 2012;
Holohan et al., 2013; Blair et al., 2014; Chen et al., 2014). Drugs
are dealt with as foreign toxic material that enters a living cell;
therefore they are overcome and counteracted by different ways.
Strategies adopted by cells include decreasing the intracellular
concentration of chemotherapeutic agents by reducing influx
or increasing eﬄux from cells, inactivation by enzymes and
modification of target sites (Figure 1).
Despite the existence of resistance mechanisms that
are specific to some classes of microbes/drugs, resistance
mechanisms that are common among all microbes and many
chemotherapeutic agents exist (Borst and Ouellette, 1995;
Viveiros et al., 2005; Kanafani and Perfect, 2008; Strasfeld and
Sunwen, 2010; Akhdar et al., 2012; Li et al., 2016).
The aim of chemotherapy is to eradicate causative
microorganisms or malignant cells. This can be achieved
when the chemotherapeutic agent reaches the site of action in
the right effective concentration and exerts its pharmacological
action.
For a chemotherapeutic agent to reach its site of action,
it should traverse many barriers. This is determined by the
pharmacokinetics of the drug, which plays the main role in
the delivery of the drug to its site of action (Chung et al.,
2016; Ramsey and MacGowan, 2016; Yang and Liu, 2016; Zhao
FIGURE 1 | General mechanisms of resistance to chemotherapy.
et al., 2016). It all starts with the absorption of the drug
through lipophilic membranes, followed by distribution to body
cells and tissues through the blood. Once the drug reaches
the intended target site and concentrates to the therapeutic
level, the pharmacological effect is seen in the form of
pharmacodynamics – the interaction of the drug with receptors
or proteins at the target site causing the body’s response.
A drug may fail achieving biological response due to eﬄux by
the target cells, which is one of the main reasons behind failure of
treatment of many diseases.
Eﬄux of drugs from cells by membrane transporters is
the most predominant and mutual mechanism of resistance
among all organisms (Tillotson and Tillotson, 2010) These
membrane transporters are proteins that belong to a superfamily
of genes called the ABC (Holmes et al., 2016; Ye et al.,
2016; Zhang et al., 2016). This review sheds light on the
different types of ABC gene family, their expression in different
microbes/malignant cells, their role as membrane transporters
and their role in development of resistance to chemotherapeutic
agents. Modulators of the expression or function of the ABC
transporter family and new methods to overcome their effects are
also discussed.
THE ATP-BINDING CASSETTE (ABC)
The ABC is the largest protein transporter superfamily present in
all organisms.
This family of genes codes for different proteins (importers
and exporters), which translocate a variety of substrates such
as sugars, amino acids, ions, peptides, proteins, cholesterol,
metabolites and toxins across extra- and intracellular membranes
(Linton, 2007; Broehan et al., 2013; Benadiba and Maor, 2016).
They are present in both prokaryotes and eukaryotes and
serve many functions. In prokaryotes they represent both influx
proteins, which carry nutrients into cells, as well as eﬄux
proteins, which expel toxins and drugs out of the cell. However, in
eukaryotes, they are only expressed as eﬄux transporter proteins
protecting the cell from toxins (Higgins, 2001; Breier et al., 2013;
Videira et al., 2014).
The common feature shared between all ABC transporters is
the fact that they are made of two domains. The first is the NBD
and the second is the TMD (Ter Beek et al., 2014). These two
domains participate in a coupling mechanism to contribute to
the main common function that facilitates import and export
(Altenberg, 2004). The NBD catalysis ATP hydrolysis and the
resulting energy is used by the TMD to translocate substances
through the membrane by conformational changes (Silva et al.,
2015). Eﬄux of drugs by ABC transporters decreases intracellular
drug concentration causing failure of chemotherapy. This eﬄux
mechanism is seen in all living cells, prokaryotes and eukaryotes
(Holland and Blight, 1999; Sharom, 2008) and will be discussed
in depth in each organism.
Human ABC
In humans, there are 49 known ABC genes classified into seven
different families (A–G) depending on their amino acid sequence
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and eventually their protein domains: ABCA (13 members),
ABCB (11 members), ABCC (11 members), ABCD (4 members),
ABCE (1 member), ABCF (3 members), and ABCG (5 members)
(Dean et al., 2001; Auner et al., 2010). They serve a variety of
functions other than drug resistance and they can be expressed
as channels, receptors and transporters (Vasiliou et al., 2008).
The members involved in drug eﬄux from human cells
don’t belong to one particular family. There are 12 transporters
reported to be responsible of drug eﬄux, however, three main
MDR transporters ABCB1 (P-gp), ABCC1 (MRP), and ABCG2
(BCRP) have a great significance in the eﬄux of a variety of drugs.
Substrates of these three MDR “omnivore” transporters belong to
different classes, not just anticancer drugs but include antivirals,
antibacterials, antiepileptics, antidepressants, antiparasitics, and
antifungals (Sharom, 2008).
The first report about the role of MDR proteins in
chemotherapy resistance was released in Ling and Thompson
(1974) when Victor Ling and Larry Thompson realized that
colchicine failed to enter cytoplasm of a Chinese hamster
ovary cell line. Furthermore they found that the same cells
were resistant to demecolcine, actinomycin D and vinblastine
(Kunjachan et al., 2013).
Expression of eﬄux transporters in humans is seen in many
organs such as the intestine, brain, liver, kidney, adrenals,
placenta, and lungs. In the intestine, liver and kidneys they
are highly expressed and hinder entry of toxic chemicals
including drugs and reduce their bioavailability and alter their
pharmacokinetics.
P-glycoprotein and BCRP are present in the epithelia of
sensitive tissues like the brain, placenta, and stem cells where
they mediate not just MDR, but also multiple drug interaction
in the membrane penetration step (Brockmöller and Tzvetkov,
2008; Kunjachan et al., 2013), which may result in toxicity
during absorption or secretion. An example is seen in the
administration of digoxin with verapamil or quinidine, which
compete with digoxin for the P-gp, overcoming it and displacing
it from the transporter binding sites, increasing digoxin blood
levels. This process can be utilized to increase systemic
exposure of orally administered Pgp substrate drugs. This is
an example of competition on the absorption level (Lin and
Yamazaki, 2003). Similarly, BCRP (ABCG2) is involved in the
competitive interactions between MTX (an anticancer drug) and
benzimidazoles (antifungal agents), which results in reduced
MTX clearance. Again, this kind of interaction can be used to
increase drug bioavailability. Interestingly, flavonoids, which are
present as flavorings and colorings in food are also substrates
exported by ABCG2. Therefore they can be used to overcome
ABCG2-mediated resistance. This is an example of competition
on the level of secretion (Breedveld et al., 2004; Noguchi et al.,
2014).
In addition to their role in drug eﬄux, ABC transporters
are reported to play a role in drug metabolism. Traditional
drug metabolism was known to consist of Phase I and Phase
II. Phase I is oxidation/reduction of the exogenous compounds
to activate pro-drugs or inactivate actives, while Phase II is
conjugation of the partially detoxified metabolites. Recently two
additional phases were added, called Phase 0 and Phase III
of drug disposition. ABC transporters play their role in these
phases by modulating the cellular entry and exit of exogenous
compounds. In Phase 0, before drugs reach intracellular targets,
transporters will control their entry and exit, which results
in either augmentation or reduction in pharmacological drug
effects. Finally, the role of ABC transporters in Phase III is
to assure complete elimination of the metabolized molecules
(Brockmöller and Tzvetkov, 2008).
Because ABC members are not just involved in drug
resistance, mutations in ABC genes can cause many recessive
genetic disorders like cystic fibrosis, neurological disorders,
retinal degeneration, cholesterol/bile transport defects, and
anemia (Dean et al., 2001). In cystic fibrosis, for example,
the cystic fibrosis trans-membrane conductance regulator
(CFTR/ABCC7) was found to be mutated in many cases (Jordan
et al., 2008).
In this review, the main focus will be on the most influential
ABC eﬄux transporters and their role in chemotherapy
resistance and failure.
Human ABCA Family
Thirteen transporters are reported as members of the human
ABCA family. The function and expression status of the most
commonly characterized members are presented in Table 1.
This family of transporters are involved mainly in resistance to
anticancer and antiviral agents (Borst et al., 2004; Li et al., 2007;
Hedditch et al., 2014).
Human ABCB Family
ABCB1 (P-glycoprotein/MDR1)
ABCB1 is an atypical membrane transporter found in the kidney,
placenta, liver, adrenal glands, intestine and blood–brain barrier
and has the most critical and leading role in drug eﬄux and
chemo resistance (Kartner et al., 1983; Higgins, 1992; Kathawala
et al., 2015; Silva et al., 2015). P –glycoprotein (P-gp)/MDR1
(ABCB1) was the first discovered eﬄux transporter and is
the most influential in contributing to drug resistance. The
relationship between P-gp over expression in tumor cells and
drug resistance and failure of chemotherapy is well documented
(Veneroni et al., 1994; Gottesman et al., 1996; Duan et al., 2004;
Yakirevich et al., 2006; Ween et al., 2015). The P-gp mechanism of
eﬄux is unclear but can be described by two different hypotheses:
One suggests that P–gp eﬄuxes molecules from within the
cytoplasm (vacuum-cleaner hypothesis) while the other from
within the cell membrane. The latter hypothesis is supported
by theoretical models and empirical in vitro experiments, which
show that P-gp identifies substrates before they reach the
cytoplasm (‘preemptive pumping’). Once this is accomplished,
the P-gp activates conformational changes resulting in ‘induced-
fit’ interaction with a wide range of MDR substrates (Figure 2).
Nevertheless, both hypotheses can be supported by the fact
that P-gp is over-expressed in the barrier forming plasma
membrane, explaining its protective mechanism toward the cell.
An experiment on Chinese hamster ovary cells proved that P-gp
constituted about 20% of the total plasma membrane proteins
intrinsically (Ferreira et al., 2015).
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TABLE 1 | Subtypes of ABCA transporters.
Subtype Expression status Notes Reference
ABCA1 Over-expressed in:
– Pancreatic ductal adenocarcinomas,
– Breast and ovarian cancers,
– Cisplatin-resistant human epidermoid
carcinoma cells.
– A cholesterol efflux pump in the cell’s lipid
metabolism pathway.
– Lentiviral knockdown of ABCA1 resensitize
chemotherapy-resistant cells.
Fitzgerald et al., 2004; Chou et al.,
2011; Mohelnikova-Duchonova et al.,
2013
ABCA2 Over-expressed in:
– Some human cancer cell lines,
– Estramustine- resistant strain of ovarian
cancer cell line,
– mitoxantrone- resistant small cell lung cancer
cell lines.
– Localized in endolysosomal organelle membranes
and expressed in many tissues of the central and
peripheral nervous systems, macrophages and
reproductive tissues (prostate, ovary, uterus).
– Antisense targeting of ABCA2 resulted in
down-regulation of ABCA2 and re-sensitization to
estramustine.
Austen et al., 2003; Davis et al., 2004;
Mack et al., 2011
ABCA4 Over-expressed in:
– Induced MDR breast cancer cell line.
– The degree of its up-regulation could be used as
marker for determining the stage of ovarian cancer
and the degree of its resistance to chemotherapy.
Liu et al., 2005; Ween et al., 2015
ABCA5 Over-expressed in:
Esophageal– doxorubicin, paclitaxel, and
vincristine resistant ovarian cancer cells
– Was first discovered in 2003. Ohtsuki et al., 2007; Saini et al., 2012;
Hlavac et al., 2013
A six to sevenfold increase in P-gp expression in the tumors
of five patients with lung metastasis after chemoperfusion of
doxorubicin for only 20 min was reported (Abolhoda et al., 1999).
This phenomenon of up regulation of eﬄux transporters as a
result of chemotherapy is known as acquired resistance. This type
of resistance also refers to cases where MDR proteins appear
in tumors of tissues where they are normally not present like
in gliomas (Kirtane et al., 2013; Kunjachan et al., 2013). Drug
eﬄux is not the only way of conferring resistance in P-gp over
expressing cells. P-gp over expressing cells are less sensitive to
different kinds of caspase-dependent cell death, including those
mediated by Fas ligand (apoptosis- inducing TNF) and serum
withdrawal. This means cells with high P-gp expression may have
a higher survival rate or less apoptosis induction (Ruefli et al.,
2000).
Another dimension of development of MDR by cancer cells
is the transfer of functional P-gp from P-gp positive to P-gp
negative cells both in vitro and in vivo (Levchenko et al., 2005).
The transfer can happen by means of extra cellular vesicles such
as exosomes explaining how some sensitive cells acquire drug
resistance (Kirtane et al., 2013).
Over expression of ABCB1 in cancer cells results in resistance
to drugs from different classes such as vinca alkaloids, taxanes,
anthracyclines, epipodophyllotoxines. A study using Paclitaxel on
Abcb1 knockout mice cells, showed accumulation of the drug
in their gastrointestinal tract and brain. This shows that ABCB1
is responsible of paclitaxel’s elimination into the bile and for
preventing it from crossing the blood–brain barrier (Schinkel
et al., 1996; Kirtane et al., 2013).
Ionizing radiation and P-glycoprotein
Radiotherapy represents one of the main pillars of cancer therapy.
It plays a major role in definitive, adjuvant and palliative
treatment. It kills cells by damaging the DNA, changing genes
and inducing cell apoptosis. Being non-selective and lethal,
the dose of radiation must be limited to minimize damage to
healthy cells. Just like in chemotherapy exposure, upregulation
of MDR eﬄux transporters like MDR1 (P-gp) happens in
response to radiotherapy (Kim et al., 2012; Wang et al., 2012).
A study using squamous cell carcinoma cell lines, T-167 and
T-409, exposed to different doses of ionizing radiation showed
overexpression of P-gp after exposure of cells to 2 Gy. This
information means exposing cancer cells to ionizing radiation
before pharmacotherapy may result in chemotherapy resistance.
This fact can be utilized in combinatorial strategies of cancer
therapy to optimize doses and regimens and to promote using
ionizing radiation preferably after chemotherapy to reduce the
risk of resistance (Shareef et al., 2008).
Polymorphism of ABCB1
Several SNPs in the ABCB1 gene were reported and were
shown to modulate resistance/response to therapy (Gréen
et al., 2006; Obata et al., 2006; Kim et al., 2009; Bergmann
et al., 2011; Peethambaram et al., 2011; Ween et al., 2015).
This is because protein expression or function is altered,
thereby resulting in differences in pharmacology and response
to ABCB1 inhibitors. For example, polymorphisms in the
ABCB1 and ABCG2 genes in AML patients may contribute
to different survival outcomes and toxicities due to decreased
drug eﬄux in AML blasts and normal progenitors. If the
patient’s cancer cells have a limited ABCB1 expression and
function, using an inhibitor could increase toxicity to the
normal bone marrow compartment while having little impact
on the leukemic cells, this means more harm than benefit
(Shaffer et al., 2012). Therefore, the goal of studying SNP
is a better understanding of inter-individual pharmacologic
variation due to polymorphism of ABCB1, which may open a
window for individualized therapy based on the patients ABC
transporter genotype (Hamidovic et al., 2010; Diaz-Padilla et al.,
2012).
ABCB1 inhibitors
Competitive inhibitors of ABCB1 are categorized into three
generations of drugs based on pharmacodynamics characteristics
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FIGURE 2 | Proposed mechanism of efflux by ABCB1 (P-gp/MDR1). (A) Pre-emptive pumping hypothesis: P-gp identifies substrates in the cell membrane and
before they reach the cytoplasm. (B) Vacuum cleaner hypothesis: P–gp effluxes molecules from within the cytoplasm.
(Kathawala et al., 2015): First-generation ABCB1 inhibitors,
including verapamil and CCBs, non-CCBs such as flupenthixol,
chlorpromazine, CSA, quinine and quinidine (Abdellah et al.,
2015). Second- generation inhibitors such as valspodar and third
generation such as tariquidar and zosuquidar are under clinical
investigation (Table 2). Unfortunately, many of the ABCB1
inhibitors may also inhibit cytochrome P450 and impair drug
clearance, putting a risk of toxicity and adverse effects to normal
cells (Pusztai et al., 2005; Kathawala et al., 2015; Li et al., 2015).
Alteration of pharmacokinetics by ABCB1 inhibitors may
necessitate decreasing chemotherapeutic doses to prevent
toxicity. However, this would be sacrificing the benefit from the
inhibition. Designing potent MDR inhibitors free from unwanted
pharmacological effects is the ultimate goal. Drugs like CSA and
Verapamil are good inhibitors of ABCB1/ABCB4 and therefore
it would be a strategy to saturate MDR1/MDR3 transporters to
increase intracellular concentrations of drugs (Amiri-Kordestani
et al., 2012).
A phase III trial by Southwest Oncology Group
(SWOG) supported the combination of CSA with induction
chemotherapy, as it results in improvement in 2-year overall
survival. Fortunately, further studies on leukemia patients proved
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FIGURE 3 | Strategies for inhibition of ABC transporters. The blue boxes represents traditional methods to overcome ABC transporters while the green boxes
represents non-traditional methods.
that administering CSA with treatment improved overall survival
from 4 to 12 months. However, there was no correlation between
chemotherapy dose and level of P-glycoprotein expression
(Shaffer et al., 2012).
An investigation to test the interaction of fourth generation
fluoroquinolones–gatifloxacin with the three dominant eﬄux
pumps: P-gp, MRP2, and BCRP was done and its results
showed that cellular uptake of erythromycin in cells with P-gp
overexpression was increased in the presence of quinidine or
gatifloxacin.
This shows that quinidine and gatifloxacin are also substrates
and can be used as inhibitors of P-gp. Further testing
showed that quinidine prevents erythromycin eﬄux by non-
competitive inhibition of P-gp whereas gatifloxacin appears to
cause competitive inhibition. The indirect inhibition of P-gp
and MRP2- mediated eﬄux by gatifloxacin is through ATP
inhibition and fluoroquinolones were proven not to be substrates
of BCRP. Knowing that P-gp in bacteria is ATP-dependent
means that inhibitors can be developed to prevent such ATP
dependent eﬄux, fighting antibacterial resistance (Kwatra et al.,
2010).
Moving to newer agents, Tariquidar’s effect as an inhibitor
was investigated in advanced breast cancer and was found to
reverse resistance to doxorubicin, vinblastine, and paclitaxel
(Walker et al., 2004; Amiri-Kordestani et al., 2012). Another
clinical trial on non-small cell lung cancer (NSCLC) patients,
however, was suspended because it resulted in toxic effects
and poor responses. Still, those contradicting results
TABLE 2 | Inhibitors of ABCB1 (P-gp/MDR1).
Class Examples Reference
First generation (a) CCBs (Verapamil),
(b) Non-CCBs (flupenthixol, chlorpromazine, CSA,
quinine, and quinidine)
Tsuruo et al., 1981; Pennock et al., 1991; Bechtel et al., 2008;
Kelly et al., 2011; Koski et al., 2012; Abdellah et al., 2015
Second generation Dexverapamil
Valspodar
Biricodar citrate
Wilson et al., 1995; Tidefelt et al., 2000; Minderman et al.,
2004; Amiri-Kordestani et al., 2012
Third generation Tariquidar, Laniquidar and zosuquidar
Elacridar
Mitotane and Annamycin
Consoli et al., 1996; Kemper et al., 2004; Fox and Bates, 2007;
Dorner et al., 2009; Li et al., 2015
Natural products Flavonoids from Chinese plants
Neochamaejasmin B
Cytarabine and halaven
Michalak and Wesolowska, 2012; Huang et al., 2014; Lopez
and Martinez-Luis, 2014; Pan et al., 2015; Long et al., 2016
Monoclonal antibodies MRK-16
MRK-17
Pearson et al., 1991; Naito et al., 1993
Others Gatifloxacin
Celecoxib
Kwatra et al., 2010; Chae et al., 2015
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don’t change the fact that Tariquidar is a potent effective
inhibitor and a lead compound with many analogs (Li et al.,
2015).
Another interesting study of MDR inhibition in cells over-
expressing COX-2 and MDR-1 has shown that celecoxib, a COX-
2 specific inhibitor, induces apoptosis and down-regulation of
MDR-1 expression (Arunasree et al., 2008; Chae et al., 2015).
This indicates that celecoxib can be considered a potential MDR
inhibitor.
ABCB4
ABCB4 (MDR3) is very similar to the ABCB1/MDR1/P-gp in
structure (Arai et al., 1997). ABCB4 protein is up-regulated in
soft tissue sarcomas (Januchowski et al., 2013; Mohelnikova-
Duchonova et al., 2013) and increased levels are associated
with a weak response to chemotherapy (Duan et al., 2004). It
was found to be up-regulated 16-times in paclitaxel resistant
ovarian cancer cell lines compared to parental cell lines. siRNA
knockdown of ABCB4 resensitizes cancer cells to paclitaxel.
ABCB4 was up-regulated 176-fold in doxorubicin- and 147-
fold in vincristine-resistant sublines of ovarian cancer cells
which proves that ABCB4 does contribute to chemotherapy
resistance just like ABCB1 (Duan et al., 2004; Morita and Terada,
2014).
ABCB11
Till 2007, few reports were published about ABCB11. However,
latest researches proved that ABCB11 is the bile salt exporter
protein (BSEP). Mutations in ABCB11 which causes deficiency of
ABCB11 increase the risk of liver cancer (Strautnieks et al., 2008).
Its role in chemoresistance is not well studied (Childs et al., 1998).
ABCB11 research has so far been focused on liver disease (Ween
et al., 2015).
Human ABCC Family
The discovery of ABCC as an eﬄux pump goes back when
some researchers reported that some lung cancer cells not
expressing P-gp show resistance to MTX, doxorubicin, etoposide
and vincristine due to increased eﬄux of drugs (Cole et al., 1994;
Grant et al., 1994). This led to the discovery of ABCC1 (MRP1).
These transporters have broad spectrum anticancer resistance
activity, making them part of the three main MDR proteins.
MRP1 specifically, has a great abundance in primary ovarian
tumor cells. A high MRP1 expression in primary neuroblastoma
was strongly correlated with poor patient outcome. However,
development of inhibitors of these MDR transporters isn’t
advancing much and the number of compounds that enters
clinical trials is limited, one of them is sulindac (Burkhart
et al., 2009). Other members of the ABCC family include
ABCC2, ABCC3, ABCC4, ABCC5, ABCC6 and 12 (Ween et al.,
2015). Overexpression of these eﬄux pumps was shown to be
associated with resistance to many anticancer drugs such as
cisplatin, etoposide, doxorubicin, vincristine, MTX and purine
analogs (Baiceanu et al., 2016). Protein expression of ABCC10
and ABCC11transporters was shown recently to be associated
with survival of colorectal cancer patients (Krizkova et al.,
2016).
Human ABCG Family
ABCG2 (Breast cancer resistance protein/BCRP/MXR)
The first report about a possible link between ABCG2 expression
and prognosis of leukemia was mentioned in 1997 (van den
Heuvel-Eibrink et al., 2007). This was followed by a debate due
to contradicting results regarding a correlation between ABCG2
and response to chemotherapy (Maliepaard et al., 1999; Doyle
and Ross, 2003; Sparreboom et al., 2005). The possible reasons
behind the contradicting results are that: first, the drugs used in
some studies were poor substrates to the protein itself. Second,
mRNA levels that were used to detect expression may not reflect
correct levels of protein expression or activity. Third, design of
some studies might be poor or inaccurate (Mao and Unadkat,
2014). Studies show that the same inhibitors used against P-gp
like the latest Tariquidar derivatives can be used for both BCRP
and P-gp (Li et al., 2015).
Exosomes and ABC
Exosomes are nano sized (50–100 nm) lipid bilayer/membrane-
bound vesicles generated and released from the cell interior.
Exosome formation is a natural process, and they are considered
as the “cargo” or “garbage bags” either excreting wastes or
transporting molecules between cells. Their role in cancer
is seen as intercellular communication, promotion of signal
transduction as well as the transfer of membrane receptors,
proteins, mRNA, and miRNAs between cells and this contributes
to tumorigenesis, metastasis, and chemo-resistance (Urbanelli
et al., 2013).
In addition, exosomes transfer messages from tumor cells to
immune and stromal cells. This contributes to the development
of the tumor niche and freedom from immune system. One of
the problematic proteins that can be transferred by exosomes
from cell to cell is P-gp leading to acquired resistance to
chemotherapy among cancerous cells. The second way by which
exosomes mediate drug resistance in cancer is by encapsulation of
chemotherapeutic agents intracellularly and their excretion out of
the cell (Zhao et al., 2015).
Claire Corcoran and colleagues developed docetaxel-resistant
prostate cell lines in 2012 and results reflected that one of the
ways cells acquired resistance was due to the transfer of P-gp by
exosomes. This acquired resistance to Docetaxel also resulted in
cross-resistance to a range of other anticancer drugs including
anthracyclines. Furthermore changes in metastasis characteristics
like invasion, motility, migration, proliferation, and growth were
developed (Corcoran et al., 2012).
Bacterial ABC
Numerous mechanisms of antibacterial resistance exist and
threaten the activity and efficacy of antibiotics. These include
enzymatic inactivation of drugs, drug target alteration and
reduced transport of antibiotics to the bacterial cells. However,
increased active eﬄux of drugs is considered the major problem
because expression of one species of multidrug eﬄux pumps can
result in resistance to a variety of antibiotics (Robertson et al.,
2005).
Bacterial cells, like mammalian cells, also express different
families of ABC transporters that also play a role in resistance
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to antibiotics (Davidson et al., 2008). After the revolutionary
discovery of eﬄux systems in humans in 1972 by Dano,
prokaryotes ABC studies began through the analysis of
histidine/maltose uptake systems in S. enterica and E. coli.
Starting from 1978, Levy and McCurry hit the road to research
about antibiotic resistance by eﬄux from bacterial transporters
by discovering the first bacterial eﬄux transporter.
Three functional classes of ABC systems exist in bacteria:
Importers, exporters and the third is involved in translation of
mRNA and in DNA repair (Higgins et al., 1986; Locher, 2016).
Some bacterial transporters are specific for certain substrates
while others provide MDR as a broad-spectrum resistance.
Bacterial MDR transporters play a role in the survival of
bacteria not just by eﬄuxing toxic chemicals but they are
also involved in infections by exporting virulence factors,
which eventually result in colonization and infecting
mammalian cells (Lubelski et al., 2007; Murphy et al.,
2016).
Bacterial transporters contributing to MDR can be classified
into five groups: the ABC superfamily, MFS, the MATE family,
the SMR, and the RND superfamily (Du et al., 2015).
Adenosine triphosphate-binding cassette-type MDR
transporters play a role in gram-positive bacterial drug
resistance, such as in E. faecalis and S. pneumoniae. However,
ABC doesn’t have the greatest role in prokaryotic drug
resistance compared to other MDR systems (Hürlimann
et al., 2016). Actually, the MFS eﬄux transporters are most
dominant in gram positive bacteria whereas in gram negative
bacteria, the RND system is the most prevailing (Sun et al.,
2014).
The first ABC type MDR bacterial transporter discovered
is the lmrA, which is a protein that is homologous to the
human P-gp (Lubelski et al., 2007). The role of lmrA in
antibiotics resistance was confirmed in a study using a drug-
hypersensitive strain of E. coli where overexpression of lmrA
in this bacteria lead to acquired resistance to antibiotics
like aminoglycosides, lincosamides, macrolides, quinolones,
streptogramins, tetracyclines, and chloramphenicol (Lubelski
et al., 2007).
Streptococcus pneumoniae has over 60 ABC transporters
(Sun et al., 2014). Most of them are importers required for
the uptake of various nutrients. Only a few ABC transporters
export toxic agents and antibiotics. Many ABC transporters
have important effects on pathogen–host interactions, either
by improving bacterial growth in nutrient-restricted conditions,
wider effects on bacterial physiology, or by reducing sensitivity
to host antimicrobial peptides or to antibiotics (Durmort and
Brown, 2015).
Fungal ABC
Fungi are eukaryotic organisms, they share a lot of similarities
with mammalian cells, which means antifungals have a low
drug selectivity compared to other drug classes, restricting the
therapeutic options for treating fungal infections.
Antifungal therapy gets more complicated as drug eﬄux
through membrane transporters contributes to MDR. The main
two MDR eﬄux transporter systems in fungi are the ABC
and MFS (Cannon et al., 2009). ABC systems in fungi have
a greater role in drug resistance due to the broad spectrum
of substrates compared to the more specific MFS (Holmes
et al., 2016). This generates a greater problem especially
in immune-compromised patients experiencing opportunistic
infections (patients undergoing chemotherapy, transplantation,
HIV patients; Ahmad et al., 2013).
Eﬄux of broad spectrum antifungal drugs such as Azoles plays
a critical role in resistance of Aspergillus nidulans, C. albicans,
and S. cerevisiae (Del Sorbo et al., 2000). Candida species and
Aspergillus are the two most deadly fungal infectious pathogens.
Fifty to sixty percentage of the opportunistic infections are caused
by C. albicans –Candidiasis.
Candida
Superficial infections caused by C. albicans are best treated
with azoles whereas the more severe fatal systemic infections
are usually treated with triazoles and recently echinocandins.
Resistance by drug eﬄux is one of the four major mechanisms
of resistance in candida. C. albicans show an overexpression of
three eﬄux pumps: CDR1 (Cacdr1p) and CDR2 (Cacdr2p), both
are ABC transporters in addition to CaMdr1p (MFS transporter)
resulting in Azole resistance (Cannon et al., 2009; Bhattacharya
et al., 2016; Tsao et al., 2016).
A recent study was undertaken to identify the role of eﬄux
pumps in azole resistance in clinical isolates of C. albicans. Thirty
isolates susceptible to amphotericin B and 5-fluorocytosine
were collected from different non-HIV-infected patients in four
hospitals in Shanghai. Rhodamine 6G was used to detect the
eﬄux activity by flow cytometry analysis. Twelve C. albicans
isolates showed resistance to at least one kind of triazoles. It was
found that azole-resistant isolates had more eﬄux pump activity,
as well as overexpression of CDR1 and CDR2 (ABC genes),
proving that these ABC eﬄux systems are the reason behind
Azole resistance in C. albicans (Liu et al., 2015).
In another experiment to understand resistance of candida
to Azole drugs, recombinant forms of C. albicans eﬄux
transporters were expressed in Saccharomyces cerevisiae. The
strains expressing the transporters had a higher resistance to
Azoles compared to the parent strain. In the same study
rhodamine 6G was used with HTS (high throughput screening)
to check the eﬄux of 1200 drugs through the pumps. Nine
compounds were found to be substrates of C. albicans eﬄux
pumps and the monoamine oxidase inhibitor clorgyline was
found to successfully inhibit both ABC transporters CaCdr1p
and CaCdr2p. It reversed the resistance to fluconazole not just
in C. albicans but in C. glabrata too. It also acts on the MFS
transporter. This means it is an important lead drug that can be
used to optimize reversing drug resistance in fungal ABC systems,
especially azole resistance in Candida (Holmes et al., 2012).
Results of an investigation using two antibodies and specific
pump inhibitors in 18 C. albicans isolates showed that there is
a higher overexpression of Cacdr1p (2- to 20-fold) compared to
Cacdr2p in resistant strains. The result emphasizes the greater
influence and contribution of Cacdr1p compared to CaCdr2p
in resistance and antifungal therapy failure (Holmes et al., 2008;
Piecuch and Obła˛k, 2014).
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Aspergillus
Aspergillus contributes to opportunistic infections in
immunocompromised patients and resistance is a continuous
problem. Triazole resistance in Aspergillus fumigatus was first
described in 1997 and has increased in frequency over the last
decade. The same eﬄux pumps and mechanisms of Candida
apply to Aspergillus (van der Linden et al., 2011).
Viral ABC
Antiviral drug resistance is composed of two subdivisions:
human’s cellular resistance to antivirals, and mutations in
Tyrosine Kinase of the virus itself. Viruses lack any transporters
because they depend on the host’s cellular mechanisms and
machinery for replication and survival. Human cellular resistance
to antivirals follows the same principles of MDR. P gp, the
playmaker of MDR is a major cause of failure of therapy in viral
infections (Hernandez et al., 2013).
Most antiviral drugs suffer resistance mainly due to the fact
that they are substrates of P-gp (Silva et al., 2015). Resistance is
mostly seen in immunocompromised patients taking antivirals
for a prolonged period of time. In such patients, expression of
eﬄux transporters is increased. A study was conducted using the
protease inhibitors ritonavir, indinavir, saquinavir, and nelfinavir
in human lymphocyte cell lines overexpressing MDR1 and MRP1
genes. The effect on the uptake of those drugs was found to be
negative. Lower concentrations of the drugs were found inside
the lymphocytes with higher transporter densities. The second
part of the test used the same drugs along with potential MDR
inhibitors for both P-gp and MRP1 (GF 120918 and MK 571)
and revealed intracellular concentrations that are equal to normal
non-resistant cell lines (Jones et al., 2001).
The role of drug eﬄux transporters (P-gp) in failure of
HIV treatment with atazanavir was demonstrated by Robillard
et al. (2013) who showed that mdr1a−/−, mdr1b−/−, and
Abcg2−/− triple knockout mice accumulate more atazanavir in
their brain and testes compared to their wild-type counterparts.
They also showed that the P-gp inhibitor elacridar increases the
concentration of atazanavir in the brain and testes of wild-type
mice compared to vehicle-treated mice.
Viral hepatitis is another type of viral infection that suffers
resistance problems with pharmacotherapy. For hepatitis B and
C, Sofosbuvir, an oral drug approved by the FDA in 2013,
have been shown to be a substrate of P-gp and BCRP. Co-
administration of sofosbuvir with intestinal P-gp inducers like
rifampin and St John’s Wort decreases Sofosbuvir’s plasma
concentration and therefore decreases it’s therapeutic effect. It
is, therefore, recommended to use this drug with P-gp or BCRP
inhibitors to enhance its intracellular concentration (Devi and
Locarnini, 2013).
Parasite ABC
Controlling the spread of many parasitic infections is more
difficult than bacterial/viral infections because of the lack of
vaccines available, the slow development of newer agents and
the fast emergence of resistance. Resistance in parasites involves
two important transporter-dependent mechanisms. The first
mechanism is through decreased drug uptake into the cell
due to the loss/down-regulation of a transporter required for
uptake. This type is associated with resistance to arsenicals and
diamidines in African trypanosomes. The second and more
relevant type of resistance is the prevalent ABC transporters
eﬄux (P–glycoprotein) (Borst and Ouellette, 1995).
Parasites are eukaryotes and they are therefore expected
to share a lot in common with mammalian cells. This
includes sharing the same set of ABC genes. Luckily, being
eukaryotic and similar to human transporters this helps in
the research field regarding resistance. Even the nomenclature
is not much different. The homolog of mammalian P-gp,
for instance, in Entamoeba histolytica is known as EhPgp1.
Furthermore it was found that within the different classes
of parasitic species there are some differences in the ABC
transporters, conferring different resistance toward different
drugs. For example comparative studies between Leishmania
and Trypanosoma ABC gene families showed differences in
the genes, resulting in differences in resistance too (Yernaux
et al., 2006). Examples of resistant parasites include the emetine-
resistant Entamoeba spp., mefloquine-resistant Plasmodium spp.,
and antimonials- resistant Leishmania spp. Latest studies on
resistance in parasites mainly focused on Plasmodium falciparum,
Leishmania, and Nematodes (Ponte-Sucre et al., 2013).
Malaria
Plasmodium falciparum is one of the five plasmodium protozoa
species and is associated with the highest morbidity and mortality
of the infectious disease –Malaria. Resistance to antimalarials
creates a great hurdle toward treatment. Mefloquine was a
successful 1st line drug against this parasite in 1984 but
unfortunately resistance was developed within 6 years. Back
then; it wasn’t clear how this resistance developed. Later, it was
proved that resistance to this drug was due to up-regulation of
the PfMDR1 gene also known as Pgh1 (Reamtong et al., 2015;
Kaewpruk et al., 2016).
Overuse and wrong prescribing patterns of chloroquine, a
drug from the same class, shows increased patterns of resistance
due to mutations in Pfmdr1/P-gp as well as P. falciparum
chloroquine resistant transporter (PfCRT). PfCRT has a dual
role in Chloroquine resistance. It is a transporter that eﬄuxes
Chloroquine and transports Glutathione (GSH) by influx to
displace Chloroquine from the Heme group, leading to failure of
therapeutic effect. According to latest genetic studies that used
the frequency of mutations as resistance markers, the higher the
number of mutations in the Pfmdr1 and PfCRT genes, the more
likely the species will develop resistance (even in combinatorial
therapy), making treatment more complicated (Patzewitz et al.,
2013).
PfATP4 is a newly discovered cation P-type transporter that is
responsible of maintaining low cystolic Na+ concentrations. New
antimalarial drugs belonging to different chemical classes like
spiroindolones, pyrazoles, and dihydroisoquinolones were found
to disrupt Na+ concentrations inside the cell. Resistance toward
these new agents unexpectedly happened due to mutations
in the PfATP4 transporter. The fact that this transporter
develops mutations in turn resulting in resistance is an
important interesting topic of research because its original
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function (homeostasis of cystolic Na+) is devoid of any eﬄux
or chemoresistance. With the latest findings of its role in
antimalarial resistance, this unique transporter could open a
window to direct research toward developing new antimalarial
drugs (Spillman and Kirk, 2015).
Leishmaniasis
Leishmaniasis is a parasitic disease caused by the bite of
Leishmania infected Phlebotomine sandflies. This parasitic
disease is very serious and prevalent in developing countries yet
it is considered one of the worlds most ignored diseases (McCall
et al., 2013). It is the second serious parasitic infection after
malaria worldwide (WHO, 2010).
Multidrug resistance (MDR) is present in leishmaniasis and
as expected, ABC transporters are a major factor (Grebowski
et al., 2016). Overexpression of the membrane-bound ABC
transporters MDR associated protein 1 (MRP1) and P-gp (on the
surfaces of leishmanias) is one of the mechanisms of antimonial
resistance (Mandal et al., 2009).
The first-line treatment for more than 70 years for
leishmaniasis was pentavalent antimonials (Sb). However,
leishmaniasis treatment is poorly developed due to the
limited number of agents available. Furthermore resistance
to antimonials results in treatment failure and increasing doses
of the drugs doesn’t stop the occurrence of resistance (Haldar
et al., 2011). Techniques and agents to counteract resistance are
under development. For example, Lovastatin is an agent that was
found to inhibit both MRP1 and P-gp, allowing accumulation of
antimonials (Sb) intracellularly (Mookerjee Basu et al., 2007).
Also, another study on sodium antimonial gluconate (SAG)
resistant-leishmania was done by coadministering Glycyrrhizic
acid (GA) with SAG. Results showed that this combination
achieved higher concentrations of SAG inside the parasitic cell.
This is due to the suppression of MRP1 and Pgp by GA. GA
(liquorice extract) has another advantage of being a cheap readily
available agent in comparison to other agents (Bhattacharjee
et al., 2015).
Nematodes
Nematodes have more ABC systems genes and greater
diversity than mammals including class 1 and class 2 ABC
systems/transporters. They have the same structure like
the mammalian ABC systems, made of two domains and
play the same MDR role in chemotherapy. Recent genetic
studies showed an association between anthelmintic selection
and ABC transporters by comparing between resistant and
non-resistant populations of parasitic nematodes (Ardelli,
2013).
Overexpression of ABC transporters, specifically P –gp
occurs in drug resistant cells post-drug exposure. Deletion/
modification of ABC genes in mice, mainly P-gp and the
multidrug resistance associated protein (MRP), enhanced
sensitivity to drugs, particularly ivermectin. A recent study
focused on comparing nematodes resistance to ivermectin and
moxidectin by experimenting the effect of P-gp inhibitors
against the two macrocyclic lactones. Investigations proved
only a partial degree of cross resistance (Ardelli, 2013).
Fortunately, MDR reversing agents/inhibitors like verapamil
used in mammalian cells successfully prevent resistance in
parasites too.
NON-TRADITIONAL STRATEGIES TO
OVERCOME EFFECTS OF ABC
TRANSPORTERS
In addition to the use of chemical agents, monoclonal antibodies
and natural products (mentioned earlier in this review) to reverse
the resistance mediated by ABC transporters, there are now non-
traditional methods evolving to overcome problems associated
with traditional ABC transporter inhibitors. These strategies
include the use of biological agents such as RNA interference
and microRNA mimetics to down-regulate the expression of
ABC family members (Shen et al., 2013; Kasinathan et al.,
2014; Guo et al., 2015), development of new drug delivery
systems that can bypass the ABC family of transporters such
as nanoparticles (Callaghan et al., 2014; Lee et al., 2014; Singh
et al., 2015; Bar-Zeev et al., 2016; Yang et al., 2016), development
of new chemotherapeutic agents that are not substrate to ABC
transporters (Su et al., 2012) and the use of ultrasound waves (Wu
et al., 2011) (Figure 3).
CONCLUSION AND FUTURE
PERSPECTIVES:
In summary, the ABC gene superfamily represents many proteins
that perform a variety of vital cell functions including influx
and eﬄux in prokaryotes, while only eﬄux in eukaryotes. Influx
through ABC transporters seen in prokaryotes, such as bacteria,
transports important nutrients and molecules into the cell. Eﬄux
of toxic foreign chemicals by ABC proteins happens in all
organisms and it’s a natural protective phenomenon. However,
it results in failure of chemotherapy by reducing intracellular
drug concentrations. In mammals, three dominant ABC eﬄux
proteins result in chemotherapy failure: P-gp (MDR1), breast
cancer resistant protein (BCRP) and the MRP1. Overexpression
of these transporters results in either specific or MDR and also
affects the success rate of different combinatorial therapies.
In fungi and parasites, proteins similar to the human
ABC transporters were found. In bacteria, however, ABC
system doesn’t seem to be the most influential. It is one of
five different systems responsible of chemotherapy resistance.
Furthermore, there are differences between gram-positive and
gram-negative bacterial drug resistance, because different gene
families dominate in each. Research regarding chemotherapy
resistance mediated by such eﬄux transporters is a never-ending
process. Investigating the different transporters, their structure,
function and most importantly their role in drug resistance helps
in optimizing drug development to overcome chemotherapy
failure. Instead of wasting money, time and effort in developing
newer agents that suffer the same resistance problem, focus
should be directed toward tackling the already existing drug
resistance. Methods used to tackle resistance by ABC transporters
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are divided into four main strategies: drugs that specifically target
resistant cells, novel nanotechnologies to provide high-dose,
targeted delivery of chemotherapy, compounds that interfere
with non-genomic transfer of resistance, and approaches
to reduce the expression of P-gp within tumors such as
ultrasound exposure that has been found to down-regulate eﬄux
transporters.
Despite considerable in vitro success of MDR protein
inhibitors, there are no compounds currently available to “block”
P-gp–mediated resistance in the clinic. The failure may be
attributed to toxicity, adverse drug interaction, and numerous
pharmacokinetic issues.
More attention should be directed toward designing potent
MDR inhibitors free from unwanted pharmacological effects
to achieve higher intracellular drug concentrations and better
therapeutic outcome. In the future, ABC transporters may be
utilized and targeted to treat diseases and to increase selectivity
toward disease-causing organisms.
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